
Lawsuit: Allergan Engages in Scheme to Delay Approval of Restasis Generic Alternatives
December 12, 2017 Allergan, Inc. is on the receiving end of a proposed class action lawsuit that accuses it of violating antitrust laws with respect to its prescription drug Restasis by attempting to 'extend its monopoly' over the market for cyclosporine emulsion eyedrops.